Actively Recruiting
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Led by George Poultsides · Updated on 2026-03-17
27
Participants Needed
1
Research Sites
499 weeks
Total Duration
On this page
Sponsors
G
George Poultsides
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 and to see how well it works in finding cancer in patients with pancreatic cancer who are undergoing surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with pancreatic cancer.
CONDITIONS
Official Title
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinically suspected or biopsy-confirmed diagnosis of pancreatic adenocarcinoma
- Planned standard of care surgery with curative intent for pancreatic adenocarcinoma
- Life expectancy of more than 12 weeks
- Karnofsky performance status of at least 70% or ECOG/Zubrod level <= 1
- Hemoglobin >= 9 gm/dL
- Platelet count >= 100,000/mm^3
- Magnesium above lower limit of normal per institution lab values
- Potassium above lower limit of normal per institution lab values
- Calcium above lower limit of normal per institution lab values
- Thyroid-stimulating hormone (TSH) < 13 micro international units/mL
You will not qualify if you...
- Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800
- Myocardial infarction, cerebrovascular accident, uncontrolled congestive heart failure, or unstable angina within 6 months prior to enrollment
- History of infusion reactions to panitumumab or other monoclonal antibody therapies
- Pregnant or breastfeeding
- Evidence of corrected QT prolongation on pretreatment electrocardiography (greater than 440 ms in males or greater than 460 ms in females)
- Lab values that in the opinion of the physician would prevent surgical resection
- Patients receiving class IA or class III antiarrhythmic agents
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Stanford University, School of Medicine
Palo Alto, California, United States, 94304
Actively Recruiting
Research Team
G
gitrialeligibility@stanford.edu gitrialeligibility@stanford.edu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
DIAGNOSTIC
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here